Showing material events only. Routine administrative filings — bylaw amendments, technical fund updates, procedural FD disclosures — are filtered out so the front page stays signal-dense.
8-K
Exec appointment
confidence 92%
filed 2026-06-30
The filing discloses the appointment of Andrew Cordell Schaap as a board member effective June 29, 2026, with concurrent appointment to the Audit Committee and Related Party Transactions Committee. While the disclosure also includes a compensatory arrangement (a 200,000-share restricted stock award), the principal disclosed action is the appointment itself. The board expansion from seven to eight members and committee assignments are the core events, making this an exec_appointment rather than exec_compensation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
The filing discloses the appointment of Tomas J. Philipson, Ph.D. to the Board of Directors effective June 26, 2026, along with his concurrent appointment to the Audit Committee and Compensation Committee. While the disclosure also includes compensatory arrangements (equity options totaling 536,428 shares), the principal disclosed action is the appointment of a director with significant government and healthcare economics experience to the board and key committees. This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Mark Capone as a Class II director effective July 1, 2026, and his concurrent appointment to the Compensation Committee. The principal disclosed action is a person taking a role on the Board and a Board committee. While the filing also details compensatory arrangements (equity grants and cash compensation), the core event is the appointment itself, making exec_appointment the most salient classification. The appointment of an experienced healthcare executive with 40+ years in diagnostics and prior CEO experience at Myriad Genetics is material to investors assessing the company's governance and strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-30
Item 5.02
Nicholas T. Meserve, currently a Managing Director, will transition to the role of CEO in Q4 2026, while incumbent Dwayne L. Hyzak transitions to Executive Chairman. This represents a material executive succession and change in leadership roles.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Perrigo appointed two independent directors, Salman Amin and Omer Gajial, to its Board of Directors effective June 30, 2026, increasing board size from 8 to 10 members. Both appointees bring substantial executive experience in consumer products, retail, and digital transformation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Guus Franke was appointed Chief Executive Officer by the Board on June 29, 2026, while continuing as Executive Chairman, representing a material executive leadership transition. Jeffrey Jagid transitioned from CEO to President. The appointment reflects the company's strategic evolution as it rebrands to Circle8 Group, Inc.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Amanda Cole was appointed as Vice President and Chief Human Resources Officer effective July 21, 2026, reporting to the CEO and overseeing global HR, communications, and EHSQ functions. The appointment also coincided with the retirement of Judith Bacchus from the same role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
Three new directors—Becky Fallon, Sean Michael Deegan, and Robert Labbe—were appointed to the board effective June 24, 2026, in connection with the company's IPO registration statement effectiveness, with specified committee assignments and independence qualifications.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 94%
filed 2026-06-30
Item 5.02
Xeris Biopharma appointed Dr. Nerissa Kreher to its Board of Directors effective July 1, 2026, expanding the Board from seven to eight members. Concurrent with this appointment, John Shannon was appointed Chairperson and Marla Persky transitioned to Lead Independent Director. Dr. Kreher received initial equity compensation of approximately $450,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 82%
filed 2026-06-30
Item 5.02
On June 26–29, 2026, Graphene & Solar Technologies appointed Daniel Kennedy and Theresa Jester as directors, appointed Paul Saffron as Company Secretary, and saw the resignation of Charles Wantrup from the Board and Kristine Woo as Interim Company Secretary. The principal disclosed actions center on the appointments of new directors and a new officer, representing material governance and leadership changes.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 93%
filed 2026-06-30
Item 5.02
Dr. William Grieco was appointed as Chief Executive Officer and Class I director of Innventure, effective October 1, 2026, following a comprehensive board succession planning process. The appointment includes compensation terms of $550,000 base salary, $1M RSU grant, and $1.5M annual equity grant. The transition was announced via press release and represents a material leadership change for the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-30
Item 5.02
The filing discloses the appointment of Jack Viellieu as Chief Operating Officer of Blue Owl Digital Infrastructure Trust, effective June 30, 2026. While the section also mentions Bradley Berkley's resignation as COO, the principal disclosed action centers on the appointment of a new officer to a senior executive role. The detailed background on Mr. Viellieu's qualifications and experience, combined with the explicit statement that his selection was not pursuant to any arrangement, confirms this is an executive appointment disclosure. This is material as it involves a change in senior management responsible for operations.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
The Board of Directors elected Bertrand Loy and Kevin Wheeler as directors effective August 1, 2026, and appointed them to specific Board committees. This is a clear executive appointment disclosure under Item 5.02. Both appointees bring substantial public company CEO experience and relevant industrial manufacturing expertise, making their appointments material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-29
Item 5.02
The filing discloses the appointment of Valeriy Kim as Chief Financial Officer effective June 25, 2026, succeeding Evgeny Ler. While the section also mentions Ler's departure and Kim's compensatory arrangements (base salary of $1,132,692, annual bonus of $1,000,000, and 15,000 shares annually), the principal disclosed action centers on the appointment of a new CFO. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-29
EX-99
The exhibit discloses the Board's approval of Mr. Rajiv Kumar's appointment as an Additional (Independent) Director effective June 30, 2026, and as Part-time Chairman (subject to RBI approval). This is a material executive appointment of a senior leadership position at a major financial institution, with detailed biographical information demonstrating his significant public-sector banking and financial-services reform credentials. The appointment directly affects governance and leadership structure.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-29
EX-99.1
Professor Duncan Murray Campbell was appointed as a director of MDJM Ltd. for a two-year term, intended to strengthen the company's professional capabilities in cultural governance and strategy.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-06-29
EX-99.2
María Consuelo Loureiro Vilarello (Chelo Loureiro) was appointed as Chief Knowledge Officer of MDJM Ltd. for an initial two-year term pursuant to an employment agreement, bringing industry credentials expected to impact the company's animation and cultural strategy.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
The Board appointed two new directors, David Endicott and Linnea Burman, effective June 29, 2026, increasing the Board size from nine to 11 members. Both appointments include full biographical details, independence determinations, and compensation arrangements.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Jonathan Collins was appointed as Senior Vice President, Finance and Chief Financial Officer of Genesco, effective August 3, 2026, following a comprehensive search process. Collins brings 30+ years of financial leadership experience, including prior roles at Walmart and America's Car-Mart. The appointment includes a base salary of $550,000, target incentive of $412,500, and long-term incentive target of $825,000.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-29
EX-99.1
The exhibit announces the appointment of Dr. Srishti Gupta as Chief Executive Officer and Board member of NovaBridge Biosciences, effective July 1, 2026. While the announcement also discloses that Xi-Yong (Sean) Fu is stepping down as CEO, the principal disclosed action is Gupta's appointment to the CEO role. The disclosure emphasizes her extensive leadership experience across biopharmaceuticals and global health, and the Board's confidence in her ability to advance the company's pipeline and create shareholder value—a material change in executive leadership at a clinical-stage biopharmaceutical company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-29
Item 5.02
David Thompson was appointed Chief Financial Officer, Principal Accounting Officer, and Treasurer of CIM Group, Inc. (formerly CMFT) effective June 24, 2026, replacing Nathan D. DeBacker. Thompson received an equity award of 30,433.658 RSUs under the 2024 Manager Plan.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Eric Hyllengren was appointed as Chief Financial Officer effective July 13, 2026, with responsibility for Principal Financial Officer and Principal Accounting Officer roles. The appointment includes compensatory arrangements consisting of a base salary of $490,000, a 40% target bonus, and an option grant of 1,650,000 shares.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Fortune Brands Innovations appointed Jesse G. Singh as Chief Executive Officer and Class I Board member effective June 29, 2026, following a comprehensive search process. David V. Barry was appointed Executive Vice President and Chief Operating Officer, transitioning from his interim CEO role. Singh's compensation package includes a base salary of $1,100,000, a bonus target of 150%, and a long-term incentive award of $6,700,000.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-29
Item 5.02
A. Jayson Adair was appointed as Chief Executive Officer effective July 31, 2026, succeeding Jeffrey Liaw. This represents a significant leadership change at the company.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
The filing discloses the Board's unanimous election of Hilla Sferruzza as a director of Frontdoor, Inc., effective immediately, and her appointment to the Audit Committee. While the Item 5.02 section also describes her standard director compensation ($90,000 cash annually plus $180,000 in stock, plus $12,500 for Audit Committee service), the principal disclosed action is the appointment of a new director with significant finance and real estate expertise to the board and a key committee. This is a material governance event affecting board composition.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
David J. Johnson, Jr. was elected as a director of Domtar Corporation by resolution of its sole shareholder on June 26, 2026. The disclosure centers on the appointment of a new director and provides his qualifications and background. While the filing also mentions a consulting agreement with Gemsbok Partners LLC, the principal disclosed action is the election of a director, making this an exec_appointment event. Director appointments are material to investors as they affect board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Three independent directors—Yi Hua, Xin Yue Jasmine Geffner, and Yuanmei Ma—were appointed effective June 25, 2026, in connection with the Company's Nasdaq listing and IPO closing, with Geffner designated as audit committee chair and qualified audit committee financial expert.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-29
Item 5.02
The filing discloses the appointment of John P. Sharp as Interim Chief Financial Officer on June 25, 2026, replacing Quang X. Pham. While the section also includes a director resignation (Steven Zelenkofske) and board realignment, the principal disclosed action centers on the CFO appointment, which is material to investors as it affects the company's financial leadership. The detailed biography and compensation terms ($455/hour for up to 24 hours/week under a Master Services Agreement) underscore the significance of this executive appointment.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Troy W. Ingianni was appointed as Chief Financial Officer, Secretary and Treasurer of TransAct Technologies Inc., effective July 1, 2026, following the retirement of Steven A. DeMartino. Ingianni brings 25+ years of financial leadership experience and was appointed by the Board on June 26, 2026.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Dr. Joe Xiao was appointed to the Board of Directors on June 23, 2026, and simultaneously appointed to three key committees (Audit, Compensation, and Nominating and Corporate Governance). The disclosure centers on the appointment action itself, not on compensation arrangements or departures. Board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-29
The filing discloses two executive changes under Item 5.02: the resignation of director Julianne Huh on June 24, 2026, and the appointment of Daniel Veikko Polvi as a director on June 29, 2026. While both events are present, the principal action emphasized in the disclosure is the Board's approval and appointment of Mr. Polvi, which includes detailed background on his qualifications and experience. The appointment of a new director to fill a vacancy is material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 92%
filed 2026-06-29
Item 5.02
Carol Juel has been appointed as Executive Vice President and Chief Executive Officer of Synchrony's Digital platform, succeeding retiring Bart Schaller. Florin Arghirescu has been promoted to EVP and Chief Technology Officer, and DJ Casto has been expanded to EVP, Chief People and Operations Officer. These appointments and promotions represent material changes to the company's executive leadership structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-29
Item 5.02
Honeywell Aerospace appointed a new executive leadership team effective upon spin-off completion on June 29, 2026, including James Currier as President and CEO, Joshua Jepsen as CFO, John Donofrio as General Counsel and Secretary, and William Lautar as Vice President, Controller and Chief Accounting Officer.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
Taylor Harris was appointed to the Board of Directors of Establishment Labs effective June 24, 2026, and concurrently appointed to the Audit Committee and Nominating and Corporate Governance Committee. Harris brings 25+ years of healthcare and medical technology experience, including prior CEO and CFO roles at major companies acquired for substantial valuations, making this a material governance event affecting board composition and expertise.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-29
NatWest Group announces the appointment of Erminia Johannson as an independent non-executive director effective 1 July 2026. This is a clear executive/board appointment disclosure. The announcement includes biographical details highlighting her extensive financial services experience, including prior roles as Group Head at Bank of Montreal and positions at Fidelity and CIBC, making this material to investors assessing board composition and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-29
EX-99.1
The press release announces the appointment of Ronen Assia as an independent director to Riskified's Board of Directors, effective June 25, 2026. This is a clear executive/governance appointment of a named individual to a board position. The disclosure identifies his background (Managing Partner at Team8, co-founder of eToro), qualifications, and expected contributions to the company's strategy, making it material to investors' assessment of board composition and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
The filing discloses the appointment of Nicholas M. Maestas as Chief Financial Officer (principal financial officer and principal accounting officer) effective June 29, 2026, succeeding Svai Sanford. While the section also includes compensatory details (base salary of $500,000, 75% bonus target, and a 2,000,000-share option grant), the principal disclosed action is the appointment of a named executive to a principal officer role, making exec_appointment the most salient classification. The appointment of a CFO is material to investors as it affects the registrant's financial leadership and governance.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-29
Item 5.02
The filing discloses the appointment of four Northfield Bancorp directors (John P. Connors, Jr., Timothy C. Harrison, Steven M. Klein, and Paul V. Stahlin) to Columbia Financial's board of directors, effective upon completion of the pending merger. This is a material executive appointment event tied to the merger transaction, with biographical details provided for each appointee and explicit reference to board size expansion from nine to thirteen directors.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-26
Item 5.02
The filing discloses both the departure of Paul Krause as Chief Legal, Compliance and Corporate Affairs Officer and the appointment of Gayle Littleton to the same role, effective June 29, 2026. While both events occur, the principal action emphasized is the appointment of Littleton to fill the critical legal and compliance leadership position. The departure is framed as supporting an orderly transition, making the appointment the salient event. This is material as it involves a named executive officer in a key governance role.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-26
Item 5.02
The filing's primary disclosure is the appointment of Joseph R. Hinrichs as a director and expected future Chair of the Board, effective June 25, 2026. While the Item 5.02 section also covers compensatory arrangements (director compensation, CEO salary/equity increases, and adoption of new compensation plans), the salient event centers on the executive appointment. The appointment of an independent director with audit committee expertise to lead the board of a newly spun-off company is material to investors assessing governance and leadership continuity post-separation.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
Item 5.02
The filing discloses the appointment of Michael L. Hammer to the Board of Directors of URSB Bancorp, Inc. and its bank subsidiary, effective July 29, 2026, with assignment to the Audit Committee and Nominating/Corporate Governance Committee. This is a clear executive appointment under Item 5.02, and board appointments are material to investors as they affect governance and oversight.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-26
Item 5.02
Daniel Bendheim's appointment to Chief Executive Officer and President effective July 1, 2026 is the principal disclosed action. While the filing also details compensatory arrangements (employment agreement with $850,000 base salary, bonus, RSU grants), the core event is the executive appointment to the top leadership role. This is material to investors as CEO appointments significantly affect company direction and governance.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 95%
filed 2026-06-26
The filing announces multiple executive leadership appointments effective 1 July and 1 September 2026, including Jessica Farrell as President North America, Edgar Basto transitioning to Chief Enterprise Performance Officer, and Geraldine Slattery assuming expanded responsibilities as President Australia. While Brandon Craig's CEO appointment was previously announced on 18 March 2026, this disclosure announces the broader executive team restructuring and new appointments that would materially affect investor assessment of leadership capacity and organizational structure.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
Item 5.02
The Board unanimously elected Anne DelSanto as an independent director effective July 1, 2026, increasing the Board size from six to seven members. Ms. DelSanto, with 30+ years of technology industry experience in cloud computing, SaaS, and AI, was also appointed to the Compensation Committee, strengthening the Board's expertise in areas aligned with the Company's strategic direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
Item 5.02
Jade Biosciences appointed Mark Eisner, M.D., M.P.H., to its Board of Directors as a Class I director and member of the Nominating and Corporate Governance Committee, effective June 25, 2026. Dr. Eisner brings 25+ years of clinical development and immunology leadership, including prior roles as Chief Medical Officer at Vir Biotechnology and FibroGen, and 11 years at Genentech/Roche, directly supporting the company's pipeline advancement.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 75%
filed 2026-06-26
Item 5.02
The filing discloses two executive changes: the departure of Chief Accounting Officer Yanina Grant-Huerta (effective July 17, 2026) and the appointment of Kevin G. Sarney as interim CFO and principal accounting officer (effective June 26, 2026). While both events are disclosed, the principal action centers on the appointment of Sarney to fill the critical CFO and principal accounting officer roles, making exec_appointment the most salient classification. The departure is secondary context to the appointment action.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 85%
filed 2026-06-26
Item 5.02
The filing discloses both the departure of CEO Josh Resnik and the appointment of Key Compton as President & Chief Executive Officer effective June 22, 2026. While both events occur, the principal disclosed action centers on the appointment of a new CEO—a material leadership change. The section also mentions Todd Aman's resignation as Chief Legal and Administrative Officer, but the CEO transition is the dominant event. The appointment of Compton, a board member since 2021 with three decades of technology experience, is the forward-looking material event that would affect investor assessment of the company's leadership and direction.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
The filing discloses the appointment of Joseph Samuels as a Class I director of Willow Lane Acquisition Corp. II effective June 22, 2026. The disclosure includes his background as founder and CEO of Islet Management and prior experience as a Partner at Och-Ziff Capital Management, along with standard representations regarding family relationships and related-party transactions. This is a clear executive appointment under Item 5.02.
View raw filing on EDGAR →
8-K
Exec appointment
confidence 95%
filed 2026-06-26
The filing discloses the appointment of Stephen Hood, the Company's Chief Executive Officer and President, to the Board of Directors as a Class II director effective immediately. This is a clear executive appointment under Item 5.02, where the principal disclosed action is a person taking on a board role. The appointment is material as it represents a change in corporate governance and board composition.
View raw filing on EDGAR →
6-K
Exec appointment
confidence 92%
filed 2026-06-26
EX-99.1
The exhibit discloses biographies of three "Newly Appointed Directors" to KNOREX LTD: Kai Zhong (corporate lawyer), Lu Liu (accounting/taxation expert), and Truong Vinh Phu Le (VP of Operations and founding member). The document explicitly identifies these individuals as newly appointed directors, which constitutes an executive appointment event. Director appointments are material to investors as they affect board composition and governance.
View raw filing on EDGAR →